Foreign drug manufacturing, testing raise regulatory and ethical concerns

JAMA discusses "a recent report from the Pew Health Group about the growing risks of substandard and counterfeit medications resulting from the increasing overseas production of pharmaceuticals and their ingredients." According to JAMA, "The report notes that the U.S. Food and Drug Administration (FDA) now estimates that as much as 40 percent of pharmaceuticals used by U.S. consumers are made in other countries, and 80 percent of active ingredients and bulk chemicals used in drug manufacturing come from foreign countries." The report "recommends that pharmaceutical companies exert tighter control over their international suppliers, that Congress provide the FDA with more resources and greater authority to oversee foreign drug production, and that a universal system be created to track drugs from production to the pharmacy," the journal writes (Kuehn, 8/24).

In related news, PBS NewsHour interviewed Arthur Caplan, director of the Center for Bioethics at University of Pennsylvania's Perelman School of Medicine, who addressed the increasing trend "of holding clinical trials in developing countries and the ethical issues raised by this research trend" (Miller, 8/23).

http://www.kaiserhealthnews.orgThis article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MGI Tech’s DNBSEQ-E25 and G99 platforms set record for sequencing applications at high altitude